Corporate Governance and Section 172 statements for applicable UK subsidiaries for year ending 31 December 2021

Section 172 Companies Act 2006 Statement

The Company’s governance architecture and processes are operated to ensure that all relevant matters are considered by the Board in its principal decision-making, as a means of contributing to the delivery of the Company’s long-term priorities of Innovation, Performance and Trust.

In the performance of its duty to promote the success of the Company and the long-term priorities, the Board has agreed to a number of matters, including listening to and considering the views of shareholders and the Company’s other stakeholders to build trust and ensure it fully understands the potential impacts of the decisions it makes for our stakeholders, the environment and the communities in which we operate.

Further disclosures detailing how, during the year, the Directors addressed the matters set out in Section 172(1) (a) to (f) of the Companies Act, can be found in the consolidated financial statements of the Group, of which the Company is a member and no additional considerations are deemed necessary for the Company as the relevant matters are all considered in the Group accounts. Copies of the consolidated financial statements can be obtained from the Company Secretary, GSK plc, 980 Great West Road, Brentford, Middlesex, TW8 9GS, England.

Glaxo Wellcome UK Limited
GlaxoSmithKline Caribbean Limited
GlaxoSmithKline Holdings (One) Limited
GlaxoSmithKline Intellectual Property Holdings Limited
GlaxoSmithKline Intellectual Property Management Limited
GlaxoSmithKline US Trading Limited
GSK Finance (No.3) plc
GSK Finance (No 2) Limited
PHIVCO UK II Limited
Setfirst Limited
ViiV Healthcare UK (No.3) Limited
ViiV Healthcare UK Limited
Corporate Governance and Section 172 statements
for applicable UK subsidiaries for year ending 31 December 2021

Section 172 Companies Act 2006 Statement

The Company’s governance architecture and processes are operated to ensure that all relevant matters are considered by the Board in its principal decision-making, as a means of contributing to the delivery of the Company’s long-term priorities of Innovation, Performance and Trust.

In the performance of its duty to promote the success of the Company and the long-term priorities, the Board has agreed to a number of matters, including listening to and considering the views of shareholders and the Company’s other stakeholders to build trust and ensure it fully understands the potential impacts of the decisions it makes for our stakeholders, the environment and the communities in which we operate.

Further disclosures detailing how, during the year, the Directors addressed the matters set out in Section 172(1) (a) to (f) of the Companies Act, can be found in the consolidated financial statements of the Group, of which the Company is a member and no additional considerations are deemed necessary for the Company as the relevant matters are all considered in the GSK Group accounts. Copies of the consolidated financial statements can be obtained from the Company Secretary, GlaxoSmithKline plc, 980 Great West Road, Brentford, Middlesex, TW8 9GS.

Beecham Group plc
GlaxoSmithKline Capital plc
GlaxoSmithKline Finance plc
GlaxoSmithKline Holdings Limited
GlaxoSmithKline Mercury Limited
Wellcome Limited
**Section 172 Companies Act 2006 Statement**

The Company’s governance architecture and processes are operated to ensure that all relevant matters are considered by the Board in its principal decision-making, as a means of contributing to the delivery of the Company’s long-term priorities of Innovation, Performance and Trust.

In the performance of its duty to promote the success of the Company and the long-term priorities, the Board has agreed to a number of matters, including listening to and considering the views of shareholders and the Company’s other stakeholders to build trust and ensure it fully understands the potential impacts of the decisions it makes for our stakeholders, the environment and the communities in which we operate.

The Company has engaged with its main stakeholder groups, including our patients, shareholders, consumers, customers and Group employees, as further detailed in the stakeholder engagement statements in the Directors’ Report and the feedback from the engagement has been considered by the Directors during the decision-making process.

Further disclosures detailing how, during the year, the Directors addressed the matters set out in Section 172(1) (a) to (f) of the Companies Act, can be found in the consolidated financial statements of the Group, of which the Company is a member and no additional considerations are deemed necessary for the Company as the relevant matters are all considered in the Group accounts. Copies of the consolidated financial statements can be obtained from the Company Secretary, GSK plc, 980 Great West Road, Brentford, Middlesex, TW8 9GS.

**Dealcyber Limited**  
**Glaxo Group Limited**  
**Glaxo Operations UK Limited**  
**GlaxoSmithKline Export Limited**  
**GlaxoSmithKline Intellectual Property Limited**  
**GlaxoSmithKline Intellectual Property Development Limited**  
**GlaxoSmithKline Intellectual Property (No.2) Limited**  
**GlaxoSmithKline Research & Development Limited**  
**GlaxoSmithKline Services Unlimited**  
**GlaxoSmithKline UK Limited**  
**SmithKline Beecham Limited**  
**ViiV Healthcare Trading Services UK Limited**  
**ViiV Healthcare UK (No.4) Limited**
Section 172 Companies Act 2006 Statement

The Company’s governance architecture and processes are operated to ensure that all relevant matters are considered by the Board in its principal decision-making, as a means of contributing to the delivery of the Company’s long-term priorities.

Disclosures detailing how, during the year, the Directors addressed the matters set out in Section 172(1) (a) to (f) of the Companies Act, can be found in the consolidated financial statements of the Group, of which the Company is a member and no additional considerations are deemed necessary for the Company as the relevant matters are all considered in the Group accounts. Copies of the consolidated financial statements can be obtained from the Company Secretary, GlaxoSmithKline plc, 980 Great West Road, Brentford, Middlesex, TW8 9GS.

Galvani Bioelectronics Limited
Section 172 Companies Act 2006 Statement
The Company’s governance architecture and processes are operated to ensure that all relevant matters are considered by the Board in its principal decision-making, as a means of contributing to the delivery of ViiV’s long-term priorities of Innovation, Performance and Trust.

In the performance of its duty to promote the success of the Company and the long-term priorities, the Board has agreed to a number of matters, including listening to and considering the views of shareholders and the Company’s other stakeholders to build trust and ensure it fully understands the potential impacts of the decisions it makes for our stakeholders, the environment and the communities in which we operate.

ViiV Healthcare Limited